Medicare (and Medicare Advantage) provide some coverage for dementia, beginning with the diagnosis, says Baumgart.
The FDA approved donanemab, which will be sold under the brand name Kisunla. The new drug helps slow decline in Alzheimer's patients with mild cognitive impairment.
The FDA granted regenerative medicine advanced therapy (RMAT) status to experimental cell therapy Lomecel-B for mild ...
FDA designation enables expedited clinical development and regulatory review timelines for Lomecel-B™ –– Second designation received for ...
LGVN READ THE FULL LGVN RESEARCH REPORT Longeveron (NASDAQ:LGVN) announced that its primary treatment, Lomecel-B, has been granted Fast Track designation by the FDA only a week after being granted ...
It's not a cure-- but it is a step in the right direction.This month-- a new medication for alzheimer's, called 'kinsul'a, ...
Novo Holdings led Asceneuron’s $100 million Series C financing. The Merck Serono spinout’s lead program is an oral small molecule designed to prevent aggregation of tau protein in neurodegenerative ...
Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering ...
Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial ...
NDAQ:PASG) Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients ...
Drug and biotech companies are seeing significant innovation in 2024. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and Pfizer (PFE) are worth retaining ...